Printer Friendly

ARES-SERONO'S RECOMBINANT FERTILITY HORMONE COMPLETES PHASE III TRIALS

 NORWELL, Mass., and GENEVA, Nov. 30 /PRNewswire/ -- The Ares-Serono Group today announced that its recombinant human follicle stimulating hormone (r-hFSH), Gonal-F(R), has completed Phase III clinical trials. A New Drug Application (NDA) has been filed with the U.S. Food and Drug Administration (FDA).
 The multinational Phase III trials were designed to assess the efficacy and safety of Gonal-F in stimulating ovarian follicular development in infertile women. In October 1992, the world's first human birth was recorded after infertility treatment with Gonal-F.
 "Ares-Serono is proud to pioneer such an important advance in the treatment of infertility. Our dream, to develop advanced therapies for the thousands of couples suffering from infertility, is coming true with Gonal-F," said Fabio Bertarelli, chief executive officer of The Group. "Ares-Serono expects Gonal-F will eventually replace the urinary-based products currently on the market."
 Identical to the natural hFSH molecule, one of the most complex molecules to reproduce, Gonal-F is among the first recombinant human glycoproteins to be obtained from mammalian host cells. Gonal-F can be produced in almost unlimited quantities, thus solving complex problems related to raw material (urine)(a) collection.
 It is estimated that infertility affects one out of six couples of childbearing age worldwide. The causes of infertility are numerous, but are generally related to three important factors: ovulatory dysfunctions, tubal damage or male factor infertility.
 The Ares-Serono Group is a leading Swiss developer and marketer of pharmaceutical and diagnostic products with executive headquarters in Geneva, Switzerland. Acknowledged as the world leader in the treatment of infertility, the Group operates subsidiaries and manufacturing facilities in more than 20 countries. Shares of Ares-Serono S.A., the parent company of the Group, are traded on the major Swiss stock exchanges. Serono Laboratories Inc., headquartered in Norwell, Mass., is the leading marketer of infertility products in the United States.
 NOTE: (a) Gonadotropins, fertility hormones, are found in minute quantities in the urine of post-menopausal women.
 -0- 11/30/93
 /CONTACT: Gina Cella of Ares-Serono, 617-982-9000/


CO: Ares-Serono Group ST: Massachusetts IN: MTC SU:

DJ-CM -- NE010 -- 8916 11/30/93 16:54 EST
COPYRIGHT 1993 PR Newswire Association LLC
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 1993 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:PR Newswire
Date:Nov 30, 1993
Words:346
Previous Article:MASSACHUSETTS ELECTRIC COMPANY RATE AGREEMENT APPROVED
Next Article:U.S. HOSPITALS SLASH SPENDING AND STAFF AS MARKET FORCES, HEALTH CARE REFORM DRIVE CHANGE
Topics:

Terms of use | Copyright © 2016 Farlex, Inc. | Feedback | For webmasters